Guggenheim analyst Seamus Fernandez downgraded GSK (GSK) to Neutral from Buy without a price target following the Q3 report. While the ...

The GSK spokesperson confirmed the company is stopping development of the anti-CCL17 antibody without providing an explanation for the action. GSK recently reached primary competition of a phase 2 ...

A: Tony Wood, Chief Scientific Officer, explained that GSK is prioritizing a 30-plus valent adult vaccine proposition due to its superior antigen coverage without diminishing immunogenicity.

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... And it does so without the diminishing immunogenicity that you see in ...

GlaxoSmithKline said its key brands held their market share and continued to stay in line with the respective category performance. GlaxoSmithKline Pharmaceuticals on October 29 reported a 16 ...

GSK claims Moderna is marketing the products in violation of its intellectual property without licenses. In the lawsuits, GSK’s legal team said the company hopes to recover a “reasonable ...

GSK said it bought the rights to the inventions when it acquired part of Novartis' vaccine business in 2015. [[nid:705778]] Healthcare COVID-19 Covid-19 vaccinations Lawsuits ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the United States, claiming that its ...